pharma-and-clinical-pharmacy-congress-2016_tracks

12 / 21

Notes:
Page 40
Pharma & Clinical Pharmacy Congress 2016
November 07-09, 2016
Volume 5 Issue 4(Suppl) Clin Pharmacol Biopharm
ISSN: 2167-065X CPB, an open access journal
conferenceseries .com
November 07-09, 2016 Las Vegas, Nevada, USA
4th International
Pharma & Clinical Pharmacy Congress
Emma Yeritsyan et al., Clin Pharmacol Biopharm 2016, 5:4(Suppl)
AP-PRP-1 antiplatelet properties of proline rich polypeptide-1 (PRP-1)
Emma Yeritsyan, M G Balasanyan, H V Topchyan, A M Avetisyan and AV Khachaturyan
1Yerevan State Medical University, Armenia
2Scientific Centre of Drug and Medical Technology Expertise, Armenia
The hypothalamic PRP-1 produced in NSO and NPO possesses multiple pharmacological properties: Immunomodulator,
antibacterial and antiviral, antitumor, neuroprotective including recently discovered cerebrovascular effects and
anticoagulation activity of PRP-1 underlay the investigation of its role on platelet aggregation mapping process. The antiplatelet
property of PRP-1 was demonstrated on ADP-tem induced method using ROTEM platelet system. The healthy volunteers
(n=22) aged 20-35 were involved in the experiment. The statistical analysis was performed using ANOVA test. Obtained
results demonstrate that the incubation of PRP-1 (in concentration 0.024 μg/μl) with blood samples characterized by standard
parameters of aggregation process (A6, MS and AUC) did not induce any significant changes on platelet aggregation process
after ADP-tem initiation. In spite of this, incubation of PRP-1 with blood samples characterized by high level of aggregation
process parameters leads to prevention of ADP induced aggregation which is appeared by decreasing of A6, MS and AUC
levels for 52%, 62% and 55,6% (p<0.01) accordingly. In case of PRP-1 incubation with blood samples characterized by low
level of baseline aggregation process parameters leads to increasing of A6, MS and AUC values for 58.5%, 85.1% and 93.9%
accordingly. It is noticeable that in both cases (blood samples with low and high level of aggregation process parameters) PRP-1
incubation turns the platelet aggregation parameters level into direction leading to their standard values. Thus, the presented
investigation indicates that PRP-1 possesses regulatory role on aggregation process. These data could be served for design and
development of novel antiplatelet agents based on PRP-1 structure.
Biography
Emma Yeritsyan is currently a PhD student at the Yerevan State Medical University. She has obtained her Bachelor’s and Master’s degree from the Faculty of
Pharmacy, Yerevan State Medical University. She has also worked at the Scientific Center of Drug and Medical Technology Expertise as an Expert. She has
published more than 15 papers in scientific journals and has also participated in several conferences.